SCHEMBL4538837

SCHEMBL4538837

O=C(NCc1ccc(OC(F)(F)F)cc1)c1ccnn1-c1ncc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.46
PDE2A O00408 1/20 0.46
EGLN1 Q9GZT9 1/20 0.45
ADRB2 P07550 1/20 0.44
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
CYP2C9 P11712 4/20 0.42
HTR2C P28335 1/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 4/20 0.42
CYP2C19 P33261 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 3/20 0.41
KCNN3 Q9UGI6 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
GAA P10253 1/20 0.41
PTGER4 P35408 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4541107 0.91 MEN1 (0.49) MAPK1PDE2AEGLN1ADRB2EPHX2
SCHEMBL4538848 0.89 SCN3A (0.47) MAPK1EGLN1HPGDSMN1; SMN2SCN3A
SCHEMBL4540440 0.88 MAPK14 (0.48) MAPK1SMN1; SMN2PTGER4LMNACYP3A4
SCHEMBL4540761 0.87 PTGER4 (0.52) SMN1; SMN2PTGER4CYP3A4
SCHEMBL4543760 0.87 PTGER4 (0.41) MAPK1SMN1; SMN2PTGER4LMNACYP3A4
SCHEMBL4543960 0.86 GRM5 (0.43) MAPK1EGLN1PTGER4CYP3A4
SCHEMBL4540280 0.84 DGAT2 (0.44) EGLN1CYP2C9HPGDCYP2C19CYP1A2
SCHEMBL4539445 0.83 MEN1 (0.54) MAPK1PDE2AEGLN1ADRB2EPHX2
SCHEMBL4542986 0.81 MEN1 (0.49) MAPK1ALDH1A1HPGDCYP2C19CYP1A2
SCHEMBL4543630 0.80 MEN1 (0.53) CYP2C9CYP2C19CYP1A2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009117421-A2 HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-09-24 WO disclosed